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ABSTRACT 
 Ubiquitin plays a major role in many cellular processes including protein degradation. 
Ubiquitin attaches to a lysine group of a substrate molecule through its carboxyl terminal end, 
resulting in monoubiquitination and the subsequent post-translational modification of the protein. 
Substrate modifications are far more complex due to seven ubiquitin lysine residues which serve 
as acceptors for the conjugation with other ubiquitin molecules. The focus of this thesis is 
centered on the elucidation of ubiquitin chain formation through catalysis of E2 cascade 
enzymes. Here, we incorporate (Nε-L-Thiaprolyl-L-lysine) site specifically at the K11 position 
of ubiquitin. The incorporated protein is deprotected forming an acceptor ubiquitin molecule, 
which we utilize for ligation with a donor molecule to construct a di-ubiquitin probe and 
conjugate with a specific E2 enzyme. Future studies are aimed at retrieving a three-dimensional 
structure for this DiUb-E2 conjugate to understand the mechanisms of multiple proteins involved 
in ubiquitin chain synthesis. 
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1 INTRODUCTION  
1.1 Ub Cascade Pathway 
Ubiquitination is highly regulated by a series of cascade proteins: activating (E1), 
conjugating (E2), and ligating enzymes (E3), which all assist in the transfer of ubiquitin to a 
target substrate. There are approximately 2, 40, and 600 known E1, E2, E3 enzymes, 
respectively. Initially, a Ub molecule becomes activated by an E1 enzyme in the presence of 
ATP to form a thioester linkage between the carboxyl-terminal glycine of ubiquitin and a 
specific cysteine residue in the active site of the E1 protein.  The activated molecule is then 
transferred to an E2 enzyme where it becomes covalently attached via transthiolation or 
aminolysis. Lastly, an E3 ligase enzyme facilitates the transfer of Ub either directly or indirectly 
to a target substrate, forming an isopeptide bond. Ub most commonly associates with a specific 
amino group from a lysine on the target molecule, although attachment to other groups.6 
 
Figure 1.1 Ubiquitin Cascade 
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Ubiquitin is transferred from multiple proteins (E1, E2, and E3) to a target substrate. A 
thioester bond is formed between the carboxyl-terminal end of a glycine residue on ubiquitin and 
a cysteine in the active site of an E1 protein. Ub is then transferred to an E2 via transthiolation. 
Lastly, ubiquitin is the transferred to a target molecule, in this case which creates an isopeptide 
bond between a lysine residue on the substrate and the carboxyl end of ubiquitin.4  
 
 
1.2 Ub Structure and the Correlation to Cellular Functions 
Ub is a highly conserved protein made up of 76-amino acids and found in most 
eukaryotic cells. The stability of Ub makes up for its rather small sequence. The protein is not 
easily denatured at high temperatures and can sustain a wide range of pH levels. This is a result 
of stable hydrogen bonding of protons in alpha and beta helices as well as at the helix/sheet 
interface. Amide protons located in the back-bone region also contribute to the stability of 
ubiquitin due to hydrogen bonds formation upon refolding. The structure of Ub is quite 
interesting, which is composed of 1 b-sheet, 3 helices, and 6 b-turns, all surrounding a 
hydrophobic core.4 
Protein modifications are diversified considering variations of different ubiquitination 
sites. Ub contains seven different lysine ubiquitination sites (K6, K11, K27, K29, K33, K48, 
K63) in addition to a methionine (M1) site, which differ in cellular functions and contributes to 
the overall complexity of the ubiquitination process. Thus, Ub can form eight different linkage 
types using any of the residues. Each linkage type results in specific interactions and facilitates 
the regulation of various biological functions. The methionine residue is associated with cell 
signaling and DNA repair. Lysine 6, 11, 27, 29, and 48 have been shown to contribute to cell 
cycle proteasome degradation. Lysine 33 and 63 facilitates in protein interactions and cell 
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signaling/trafficking, respectively.16 Ubiquitination at the K63 position has also been shown to 
correlate with cell autophagy. Degradation of substrate proteins has been shown to involve 
multiple ubiquitin chains which are joined specifically by Lys48 on the N terminus of one Ub 
molecule and the carboxyl group of Gly76 of another Ub molecule. The post translational 
modification made on a substrate, whether degradation or cellular transportation to a certain site, 
is dependent on the polymerization state via monomeric or polyubiquitinated linkages to a target 
protein. The attachment of Ubto the lysine residue of a substrate molecule acts a signal usually to 
target the substrate for degradation by the 26S proteasome, which relies heavily on multiple 
protein interactions.20 
 
 
Figure 1.2 Structure of Ubiquitin 
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Ubiquitin and its seven lysine residues and one methionine binding sites shown with 
depicted cellular function. Cellular modifications are dependent on the linkage type of Ub to a 
particular substrate. Substrate molecules can be ubiquitinated at any one of the lysine or 
methionine binding residues. Substrates can even be polyubiquitinated, which is associated with 
the multiple attachment of ubiquitin molecules. This contributes to the overall complexity of the 
ubiquitination process considering different mechanisms and cellular modifications.4,5   
 
 
1.3 Ub Chain Formation 
Ub associates with a substrate molecule through an isopeptide bond between the carboxyl 
end of ubiquitin and a primary amine of the substrate, resulting in monoubiquitination of the 
substrate. The seven different lysine positions all serve as acceptors for conjugation with other 
ubiquitin molecules. Any of the exposed amino ends can function as an acceptor to the carboxyl 
group of a Gly residue of other Ub molecules, which adds multiple chains onto a substrate with 
different linkage types. As a result, substrates can be labelled for any particular function, 
predominantly for degradation. Essentially, the post-translational modification of a substrate is 
dependent on the chain linkage type.6  
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Figure 1.3 Ubiquitin Linkages 
 
Different types of ubiquitination. A. Homogeneous polyubiquitination, which involves 
the multiple attachment of ubiquitin molecules at the same linkage or lysine residue. The 
exposed amino end of the same lysine residue (K48) acts as an acceptor to the carboxyl end of 
glycine residue on the previous ubiquitin molecule. B. Heterogeneous polubiquitination, which 
involves the multiple attachment of ubiquitin molecules via different linkage residues. C. 
Monoubiquitination of a substrate at the K48 position of ubiquitin. Monoubiquitination of this 
sort involves the covalent linkage of the carboxyl end if ubiquitin to the lysine end of a substrate. 
D. Mulitple monoubiquitination of a substrate. Instead of ubiquitin molecules associating with 
each other to create poly uB chains, multiple ubiquitin molecules associate with a specific lysine 
residue on the substrate. E. Noncanonical ubiquitination, which involves attachment of ubiquitin 
to a residue other than lysine on the target substrate.6  
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1.4 Currently Known Mechanisms for Ub Chain Synthesis 
The conjugation of Ub to a target substrate is facilitated by a series of E1, E2, and E3 
enzymes that function to activate, transfer, and ligate Ub to a target substrate. The mechanisms 
by which ubiquitin is transferred to a substrate have been publicized by recent studies. The area 
of numerous studies has been centered heavily on the transfer of Ub from an E2 to E3 and from 
an E3 to a substrate molecule.  
Recent studies have shown two different mechanisms in the transfer of Ub to substrate 
molecules. The really interesting new gene (RING) and related U-box E3 ligase proteins catalyze 
the transfer of Ub from an E2 to a substrate directly. This is carried out by binding of the E3 
ligase to the E2-Ub intermediate and to the substrate simultaneously. UBE2L3, an E2 
conjugating enzyme, interacts with E3 RING-containing ligases. Instead of forming a thioester 
complex with ubiquitin, RING-like E3 proteins act as mere scaffolds to allow the direct transfer 
of ubiquitin from an E2 protein to a substrate.24 The interaction between UBE2L3 and RING-like 
E3 proteins is facilitated by non-covalent interactions in which two E3 zinc (Zn2+) ions 
coordinate to form a platform for binding.15,25 The interaction of E2s with substrates either 
directly with E3 ligases or indirectly, suggests a variation in the mechanism for these 
proteins.11,13,19 
Unlike RING-E3 ligases, HECT and RING-between-RING ligase proteins utilize a two-
step mechanism for the ubiquitination of substrates. Members of the HECT E3s contain a HECT 
domain, which is characterized by a C-terminal region comprised of 350 amino acids. The N-
terminal region of the HECT domain determines substrate specificity and is based on a specific 
amino acid sequence. As a result, HECT E3s are categorized into three sub families: Nedd4 
(contains WW domain), HERC (contains RLDs), and “other” HECT E3s (contains neither WW 
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or RLD domain).14 Ub is initially transferred from the E2 to the active site cysteine within the 
E3, which results in the formation of an E3-Ub intermediate.3 Ub is then transferred from the E3 
to the substrate. UbcH7, a well-known ubiquitin-conjugating E2 enzyme, forms a thioester bond 
with ubiquitin and associates with a specific domain of HECT E3 ligase proteins. The 
association of the UbcH7-ubiquitin conjugate with an HECT E3 ligase protein catalyzes the final 
attachment of ubiquitin to substrates, considering the formation of an intermediate thioester 
complex. It has been shown that the HECT domain of E3 ligase proteins contain a catalytic 
cysteine residue in the C-terminal lobe and an E2 binding domain in the N-terminal lobe. The 
lobes for each domain are flexible enough to allow suitable positioning of the catalytic cysteine 
towards the E2-Ub bond to allow transthiolation of ubiquitin from the E2 to E3 protein. It is 
apparent that E2 proteins must also contain two important domains: one containing the catalytic 
cysteine residue for the transfer of Ub from an E1 protein and the other bearing the binding site 
for an appropriate E3 protein considering the structural similarity of E2 and E3 enzymes. In all 
cases, interaction and binding of proteins to facilitate Ub transfer is specific and must be 
enzymatically sufficient.19,23 
 
Figure 1.4 Members of Human E3 Ligase Proteins 
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The 3 subfamilies: NEDD4, HERC, and “other” HECTs. which are grouped according to 
the N-terminal region of the HECT domain. Substrate binding is based on the specific amino 
acid sequence located in the N-terminal to the HECT domain. Nedd4 family is characterized by 
an N-terminal C2 and WW domains. HERC contains an n-terminal RLD domain, while “Other” 
HECT E3s contain neither.23 
 
1.5 Restrictions and Regulations for Ub Catalytic Chain Synthesis 
Binding of substrates and the interaction with proteins for any given E1, E2, or E3 is 
distinct and specific and may even require the aid of other small molecules. For example, all 
members of HECT E3 ligases are characterized by the HECT domain which contains the 
catalytic cysteine residue in the C-terminal lobe and E2 binding domain in the N-terminal, but 
not all interact effectively with E2 proteins.24 The HECT domain of SMURF2, a member of the 
Nedd4 sub-family of E3s, interacts ineffectively with the E2 protein UbcH7 compared to other 
E3 ligases. SMAD7 binds to both the HECT domain of SMURF2 and UbcH7 and acts as an 
auxiliary protein to allow necessary interaction between SMURF2 and UbcH7. In the absence of 
SMAD7, SMURF2 exists in an inactive form in which the interaction between the C2 and HECT 
domains serve as an auto-inhibitory function. In the presence of SMAD7, the C2 and HECT 
domain of SMURF2 become displaced. The interaction of SMAD7 with SMURF2 is seen in the 
regulation of TGF-b signaling pathway. SMAD7 consists of an amino-terminal domain (NTD), a 
linker region containing a PY motif that binds to the WW domains of SMURF2, and an MH2 
domain that interacts with TGF-b receptor complex.26 Crystal structures reveal NTD binding of 
SMURF2 to both HECT and UbcH7, suggesting catalyzed efficiency of the domain for E2 
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binding and ubiquitination. This shows the regulation for some HECT domains by interaction 
with certain molecules, which allows ubiquitination of a substrate only when necessary.  
Although a general concept for the ubiquitination process is defined, the specifics for 
how a substrate is recognized and the role different proteins play during interaction with others is 
still quite ambiguous. Members of the Nedd4 family predominantly form K63-linked ubiquitin 
chains, while other HECT E3 ligases, such as E6AP, form K48-linked chains. The mechanisms 
by which a substrate is ubiquitinated is still not clear and remains somewhat unresolved.14  
 
Figure 1.5 SMAD7 Interactions with SMURF2 
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Interaction of SMAD7 with SMURF2, a member of the Nedd4 E3s, and the E2 UbcH7. 
The interaction of SMAD7 with these certain proteins is still not fully understood, but current 
studies suggest a capable mechanism. The binding of SMURF2 HECT and C2 domains results in 
the auto inhibition of the E3 and its inactive form, which occurs in the absence of SMAD7. In the 
presence of SMAD7, the two domains become dissociated and the E3 becomes active and 
responsive to E2 binding. SMAD7 consists of an NTD and MH2 region connected by a PY 
motif. The PY motif interacts with two WW domains of the E3, while the MH2 domain has been 
shown to interact with TGF-b receptor complex in the TGF-b signaling pathway. NTD plays a 
major role in ubiquitination as it specifically binds to both the HECT region of SMURF2 and the 
E2 UbcH7, allowing efficient interaction between the E2 and E3 proteins.26  
 
 
1.6 An Approach towards Ub Catalytic Chain Synthesis  
It is understood that ubiquitin chain formation is catalyzed by a series of cascade 
proteins, however, the mechanisms behind these interactions are poorly understood. Here, 
we focus primarily on E2 proteins because they are key mediators in the ubiquitination 
process and govern the switch between chain initiation and elongation. During ubiquitin 
elongation, it is the E2 protein which catalyzes reaction of an acceptor Ub molecule 
bearing an exposed lysine residue to a donor Ub molecule. The acceptor Ub molecule 
nucleophilically attacks the C-terminal end of the donor Ub, resulting in a tetrahedral 
intermediate. Formation of the tetrahedral intermediate is transient and provides inability to 
capture a clear image on the structure during Ub chain elongation. Therefore, designing a 
more stable di-Ub probe 3 which can be conjugated to a specific E2 protein is important for 
understanding and determining cellular modifications and interactions with other 
11 
molecules. This di-Ub-E2 conjugate 4,6 functions as a mimic of the transition state 2 
during Ub elongation, which grants dichotomizing the roles of Ub chain formation. With 
this, we can aid in resolving undistinguishable issues, including mechanisms of ubiquitin 
chain synthesis, Ub assembly on a substrate, and other regulatory events that occur. Our 
approach is centered on generating a di-Ub-E2 conjugate in hopes of retrieving X-ray 
crystallography to provide better understanding the mechanisms behind Ub chain linkages.2  
 
 
Figure 1.6 Elucidating Formation of E2 Catalyzed Ubiquitin 
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1.7 Overview and Strategy on Di-Ub Probe 
Construction of our Di-Ub probe 3 is centered on four basic steps involving synthesis, 
incorporation, deprotection, and ligation of an unnatural amino acid, which will be discussed in 
greater detail in chapters 2-4. A specified amino acid can be incorporated into ubiquitin through 
an isopeptide bond or another stable, complementary group in response to an amber stop codon. 
After generating the protein of interest containing the incorporated UAA, the acceptor Ub 
molecule can be ligated to a donor Ub utilizing native chemical ligation to generate the di-Ub 
probe. This is useful as it allows the various roles of ubiquitination to be accessed. The 
framework of the di-Ub probe is outlined.  
 
Figure 1.7 Synthesis of Di-Ub Probe for Conjugation with an E2 Enzyme 
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Steps for construction of the di-Ub probe. The first step includes synthesis of the UAA, 
followed by incorporation of the UAA into ubiquitin at a specific site. Incorporation of the UAA 
is achieved by integration into a host genome and generated in large amounts. The UAA is 
deprotected to create a reactive molecule which acts as an acceptor ubiquitin to another ubiquitin 
molecule.   
1.7.1  Design of Di-Ub Probe by UAA Synthesis 
Construction of the di-uUb conjugate is initiated with synthesis of an unnatural amino 
acid. There are 21 amino acids commonly found in human cells which are necessary for the 
synthesis of proteins. The physical and chemical properties of each amino acid are heavily 
dependent on the R group side chain, which allows differentiation in hydrophobicity, size, 
charge, and shape. Naturally occurring amino acids form polypeptide bonds with one another 
and are incorporated into proteins by RNA transfer.  
DNA mutagenesis, which involves the site-specific replacement of any amino acid in a 
protein sequence, has played a significant role in determining structures and biological activity 
for proteins. New discoveries and techniques have also allowed the expansion of amino acids, 
which are not commonly found in human cells. Unnatural amino acids are produced by 
chemically modifying a natural amino acid to construct a closely similar molecule. Analogue 
modifications include alanine/glycine derivatives, b-amino acids, and linear core amino acids. 
Synthesis of our unnatural amino acid, Nε-L-Thiaprolyl-L-lysine involves a modified four-step 
reaction, which yields a lysine derivative containing a thiazolidine ring.1  
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1.7.2 Design of Di-Ub Probe by UAA Incoporation 
Incorporation of the synthesized unnatural amino acid into a specific protein site is the 
succeeding step for the development of the di-ubiquitin conjugate, which contributes to various 
strategies and applications in unnatural amino acid mutagenesis.  
The central dogma of cellular biology outlines the process for the assembly of proteins. 
During protein synthesis for natural amino acids, DNA is converted into protein by a two-step 
reaction with utilization of appropriate enzymes. First, DNA is transcribed into messenger RNA 
in the nucleus which is then moved to the cytoplasm to be translated into protein. The mRNA 
strand serves as the template for protein synthesis because it carries the necessary codons, which 
are sequences of three amino bases. Protein synthesis occurs when the small ribosomal unit 
attaches to the mRNA strand and recognizes the AUG start codon. The aminoacyl tRNA 
synthetase contains two binding sites and activates a tRNA/amino acid pair. Protein synthesis 
begins when the first binding site recognizes a methionine amino acid, resulting in binding of 
ATP and the subsequent release of a pyrophosphate molecule. Activated tRNA containing the 
anticodon sequence binds to the second site and the tRNA/amino acid pair (Met-tRNA) is 
released from the enzyme to initiate the synthetic process. The tRNA bearing the anticodon 
attaches to the start codon sequence on mRNA with assistance of the large ribosomal unit. 
Elongation of the peptide sequence occurs when another tRNA carrying molecule bearing an 
amino acid binds to the ribosomal complex and associates with the mRNA codon sequence. 
Consequently, each natural amino acid has a specific aminoacyl tRNA synthetase molecule that 
activates the tRNA/amino acid pair. Protein elongation continues until the ribosomal unit reaches 
the stop codon UAG on mRNA.21,22  
15 
Successful incorporation of unnatural amino acids at particular sites in proteins involves 
construction of a tRNA synthetase that doesn’t recognize host tRNA and only aminoacylates the 
tRNA containing the appropriate UAA. The tRNA/synthetase pair has to be engineered from a 
host, typically strains of E. coli cells, which occurs by mutating host tRNA that isn’t 
recognizable by its synthetase. The production of evolved orthogonal tRNAs from an original 
source is attained by a series of negative and positive selection. The process of negative and 
positive selection involves constructing a library of E. coli cells containing mutant tRNAs in the 
presence and absence of cognate synthetases. In negative selection, a tRNA library is introduced 
into E. coli cells with a mutant gene in which amber nonsense codons are added at specific sites. 
Cells are destroyed when the suppressor tRNA is aminoacylated by an endogenous synthetase. 
Consequently, cells that undergo aminoacylation of orthogonal tRNAs survive, which are 
utilized in the positive selection. In this process, tRNA aminoacylation with a cognate synthetase 
leads to cell survival as a result of positive selectivity. Combination of positive and negative 
selection also generates an evolution of synthetases which assists the aminoacylation of cognate 
tRNA with the UAA of interest. Synthetase variants, which are constructed by randomizing 
residues in the binding pocket, are able to specifically recognize an UAA.22 
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Figure 1.8 Orthogonal tRNA/tRNA Synthetase Pair for UAA Incorporation 
 
A. E. coli tRNATyr, which is one of approximately 20 canonical tRNAs. The evolution of 
orthogonal tRNA involves generating a suppressor tRNA library which contains a mutant gene 
in which amber nonsense codons are introduced at sites to substitution by other amino acids. B. 
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The process of negative and positive selection for a suppressor tRNA library. In the negative 
selection, tRNAs aminoacylated by orthogonal synthetases result in survival for E. coli cells. 
These tRNAS are then subjected to a positive selection in the presence of a cognate synthetase. 
Again, tRNAS aminoacylated by orthogonal synthetases grant cell survival.21  
 
 
1.7.3 Design of Di-Ub Probe by Native Chemical Ligation 
After successful incorporation of the unnatural amino acid, the acceptor Ub is used for 
ligation with another expressed protein that serves as the donor ubiquitin. This method known as 
native chemical ligation joins smaller peptide fragments together and involves two fully 
deprotected molecules. Our acceptor Ub molecule contains an N-terminal cysteine residue, 
which enables nucleophilic attack on the C-terminal thioester present on the donor ubiquitin. The 
reaction involves thioesterification to generate an intermediate, which undergoes an S to N acyl 
transfer mechanism to form the respective peptide bond. This reaction serves to generate our di-
Ub conjugate.8 
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Figure 1.9 Native Chemical Ligation 
 
 
The mechanism involves transthioesterification in which a nucleophilic N-terminal 
cysteine reacts with a C-terminal thioester to form a reactive thioester intermediate. The reaction 
undergoes an irreversible S to N acyl transfer due to the instability of the intermediate, creating a 
peptide bond. 
 
1.8 Current Models of E2 Catalyzed Ub Chain Synthesis 
Mutations and dysfunctions in E2 proteins are becoming a huge concern as they have led 
to many human diseases, such as cancer and other neurological illnesses. Therefore, 
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comprehension on the role of E2 proteins in ubiquitination is vital for an approach towards future 
treatment options for such diseases. Understanding the underlying mechanisms for these proteins 
is necessary for insight on interactions with other proteins. As a result, scientists can control and 
regulate certain protein-protein interactions, which aids in future studies and determining 
unresolved protein structures and functions.  
 E2 enzymes have an important role in ubiquitination by serving as intermediaries 
in the three-step cascade, which results in the transfer of ubiquitin from an E1 to an E3 protein. 
Ubiquitin conjugating proteins are characterized by a conserved 150 amino acid catalytic core 
known as the ubiquitin conjugation domain (UBC), which contains the catalytic cysteine. This 
region is what facilitates formation of a thioester bond with ubiquitin. Consequently, ubiquitin 
transfer relies heavily on the reactivity of E2 proteins and its nucleophilic regions, including 
cysteine groups.2,10 
Ub conjugating enzymes possess a wide range of functions. Some E2s have been reported 
to catalyze Ub chain formation through a non-covalent backside binding site that is distant from 
the active site cysteine. The backside binding site of an E2 enzyme, Ubc13, positions the 
ubiquitin E2 Mms2 to facilitate K63 chain synthesis. Other E2s, such as Ube2D3 and Ubc9, 
behave in the same manner as Ubc13 by using the backside binding site to interact with Ub or 
SUMO for ubiquitin chain elongation. Current advances in understanding the E3 ligase proteins 
continue to show new E2 activities during Ub chain synthesis.2   
Studies and images have provided evidence regarding the structure of ubiquitin 
conjugating proteins, which hint that other regions of E2 proteins contribute significantly to 
enzymatic activity. For instance, high resolution three-dimensional images of the E2 protein 
Ube21 indicates three conserved residues that play a substantial role in the transfer of ubiquitin 
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like SUMO protein to a substrate by activating the substrate acceptor lysine. The important E2 
residues (Asn85, Tyr87, and Asp127) contribute to the activation of the substrate molecule by 
lowering the substrate lysine pKa, which allows nucleophilic attack of the conjugated Ube21-
SUMO thioester bond. These regions of E2 proteins are important because mutations yield 
changes in their catalytic function. A mutation of Cdc34 (Asp127 homologue) in yeast E2 
proteins resulted in a change from poly-ubiquitination to mono-ubiquitination of substrates, 
although ability of ubiquitin to attach to the substrate was not hindered. When Ser120 (Asp127 
homologue for human E2 protein) is mutated to alanine or threonine, the activity of the E2 is 
either downregulated or upregulated, depending on the position of the amino acid. Both 
examples illustrate the importance of specific conserved regions of E2 proteins and how 
disruptions in these sites could affect the enzymatic function of E2 proteins in response to the 
substrate lysine towards the catalytic cysteine. With this in mind, various E2 proteins and their 
structures can be analyzed in order to determine how they work and interact with other 
proteins.10 
 
1.9 Structure of Di-Ub Probe and Model for E2 Catalyzed Ub Chain Ligation 
Our di-Ub probe can be conjugated to a specific E2 protein through disulfide formation 
and Michael addition. Construction of the di-Ub-E2 conjugate is necessary for mimicking the 
transition state during Ub chain elongation, in which an acceptor Ub molecule is added onto the 
Ub chain. During Ub chain formation, the C-terminal end of the donor Ub molecule is associated 
with a cysteine in the active site of the E2. The E2 then facilitates appropriate configuration 
allowing a specific lysine residue of an acceptor Ub to nucleophilically attack the C-terminal end 
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of the donor Ub, linking the two Ub molecules together. By constructing a di-Ub-E2 conjugate 
we can access Ub chain formation and better understand the roles of Ub formation and transfer.  
 
1.10 Elucidating the Formation of E2 Catalyzed Ub Synthesis through X-ray 
Crystallography 
Generation of a di-ubiquitin conjugate provides great opportunity on future studies, in 
terms of interactions with other proteins and enzymatic mechanisms. Here, we hope to reveal 
mechanisms of E2 catalyzed Ub chain ligation by obtaining a well-defined three-dimensional 
crystal structure of our di-Ub probe conjugated with a specific E2 enzyme, Ube2s. 
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2 SYNTHESIS OF THZK  
 
2.1 Synthetic Scheme of ThzK 
This chapter will focus on synthesis of the unnatural amino acid, Nε-L-Thiaprolyl-L-
lysine (ThzK). Initially, our UAA is synthesized using a five-step mechanism, but later modified 
via four-step mechanism for improved yields and enhanced incorporation into protein. Synthesis 
of the UAA is followed by purification via HPLC, therefore the reported values are 
representative of a purified product. The mechanisms are discussed.  
 
Figure 2.1 Synthetic Scheme for Unnatural Amino Acid 
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The UAA is generated with a five-step mechanism. Steps include conversion of an OH 
group to a methylated form followed by reduction to a free amine. The free amine is coupled 
with a carboxylic acid to yield an amide product. The methylated form is converted back to non-
methylated form to a hydroxyl group. The final step undergoes reduction of two Boc groups to 
yield the target product.  
 
Non-methylated ThzK was synthesized with a five-step mechanism. The reaction 
involves methylation of a carboxyl group via SN2 mechanism and the subsequent reduction of a 
carboxybenzyl (Cbz) protecting group utilizing hydrogen gas. The next step involves coupling 
between the generated free amine and carboxylic acid, resulting in the formation of an amide 
product containing a thiazolidine ring. In this step, the carboxylic acid is deprotonated and reacts 
with a water-soluble carbodiimide to form a reactive o-Acylisourea intermediate. The unstable 
intermediate is reactive towards a free amine, which allows conjugation for efficient amide 
formation. This step is critical, as it was modified from the original protocol appropriate to the 
mechanism. The original protocol involved coupling between the primary amine and carboxylic 
acid followed by addition of DMAP and EDC. However, the mechanism often resulted in low 
yield and was modified accordingly. The fourth step involves conversion of the methylated 
(OMe) group to a hydroxyl group, followed by reduction of tert-butyloxycarbonyl (Boc) under 
acidic conditions.7  
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Figure 2.2 EDC Coupling Mechanism 
 
 
A modification to the third step of the synthetic scheme was obtained according to the 
coupling mechanism, as stated above. Initially, DMAP 28 deprotonates the carboxylic acid 27, 
which enables a nucleophilic attack on EDC 30. Addition of the primary amine 32 creates an 
unstable o-Acylisourea intermediate 33, which is removed to generate an isourea by-product 34. 
This also results in formation of the coupled amide product 20. Following this protocol resulted 
in higher yields for the third coupling step.  
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2.1.1 Deprotection using TFA as a Reducing Agent 
The most common removal for Boc groups require the use of strong acids, such as TFA. 
Tert-Butyl carbamates are cleaved under these conditions to yield free amines. However, use of 
TFA as a reducing agent can produce undesirable side products, such as TFA salts. Purification 
of the final step via ether precipitation (precipitating the product from the reaction mixture with 
cold ether) was rather challenging, often resulting in low yields (less than one gram). This is 
likely due to the production of TFA salts and the inability of product to precipitate out of 
solution. Solubility of a molecule plays an important role in precipitation and it highly possible 
that the high solubility of the product makes ether precipitation somewhat difficult. It is also 
important to consider the potential harmful effects of trifluoroacetic acid salts, which are 
detrimental to growing cells. Such contaminants could lead to a substantial decrease in cell 
proliferation and a subsequent decrease in expressed protein. As a result, the procedure was 
improved with intentions of increasing the overall yield of the UAA and limiting the amount of 
harmful side products.7,21  
 
 
2.2 An Improvised Mechanism on the Synthesis of ThzK 
2.2.1 Deprotection using Hydrochloride as a Reducing Agent 
The modified protocol involved using a 4M solution of hydrogen chloride as a reducing 
agent, instead of TFA. Hydrogen chloride is a more suitable reducing agent as undesirable side 
product are limited. When HCl is used for the deprotection, the product is obtained as a HCl salt, 
which is less harmful, more soluble and easier to handle. Therefore, a modified procedure was 
generated in anticipation for increasing the amount of UAA produced and suitable incorporation 
into cell for protein expression.  
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2.3 Yield Analysis on Improvised Synthetic Scheme 
The yield for the modified protocol produced comparable results to the original synthetic 
scheme instead of substantially increasing the yield. Similarly, the amount of UAA obtained was 
less than a gram. According to the data in in Figures 2.2 and 2.4, the yield of the unnatural amino 
acid shows a significant decrease during the fourth step, involving conversion of the methoxy 
group to hydroxyl group. The step involves generation of carboxylate ions which are collected in 
an aqueous layer during extraction and purification techniques. The aqueous layer is acidified 
with a 5% citric acid solution to give the target product., which then becomes soluble in organic 
layer. The decrease in yield could be a result of many steric and electronic factors in the reaction. 
Also, the low polarity of THF solvent utilized in the reaction could hinder product formation. 
Many studies have also revealed that methylated forms of UAA display higher yields and better 
incorporation into cells. Methylated UAAs are less charged and are believed to be better 
transferred into cells. As a result, the protocol was modified further using a four-step reaction 
that yielded a methylated unnatural amino acid in attempts for substantially increasing the 
overall yield.21  
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Figure 2.3 Yield Analysis for Modified Approach using HCl as a Reducing Agent 
 
 
Data represents the first attempt using modified protocol. Each step shows the formula 
weight, mass, and mmol in which the yield is calculated based on the preceding step. Results 
using HCl as a reducing agent produces similar results as in original scheme, although 
detrimental side products are reduced. 
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also during incorporation (will be discussed further in chapter 3). The first three steps of the 
initial protocol involving methylation, reduction, and coupling were unchanged. However, the 
fourth step involving conversion from a methoxy to OH group was depleted. To help in removal 
of impurities, the third step was subjected to purification via column chromatography. The final 
step involved reduction of the Boc group using a 4M solution of hydrogen chloride, as 
mentioned before. 
 
 
 
Figure 2.4 Yield Analysis for Methylated UAA 
 
 
The data includes the yield for each compound is shown, which is calculated from the 
preceding step. The mmol for each compound is determined by the molecular weight and amount 
produced. 
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2.4 Conclusions 
An efficient method for synthesizing and purifying the UAA was established after 
numerous trials, which generated a higher yield in product and decrease in unfavorable side 
products. A convenient and suitable synthesis method is essential for a large-scale production of 
UAA. 
 
2.5 Methods and Materials 
1HNMR was analyzed using Bruker 400 MHz spectrometer in Chloroform-d and deuterium 
oxide.  
Compound 17 - Synthesis of Boc-L-Lysine(Cbz)Methylester 
 BocLys(Cbz)OH (7.23g, 19.0 mmol) was dissolved in DMF (40 ml), followed by 
addition of potassium carbonate (5.25g, 38.0 mmol). The solution was allowed to cool to 0o C 
before dropwise addition of iodomethane (1.05 ml, 24.7 mmol). Completion of the reaction was 
monitored after overnight stirring at room temperature using thin layer chromatography (Hex:EA 
= 1:1). The reaction mixture was dissolved in ethyl acetate (50 ml) and extracted twice using 
water (100 ml) to remove excess DMF. The organic layer was then extracted using brine (100 
ml) and the combined organic layers were concentrated to dryness and purified using column 
chromatography (hexane: ethyl acetate = 1:1).  
Compound 18 - Synthesis of Boc-L-Lysine Methylester  
 Boc-L-Lysine(Cbz)Methylester (1.0 eq) was dissolved in a mixture of ethyl acetate (40 
ml) and ethanol (10 ml). Palladium (10%, 0.39 mmol) was added to the stirred solution and 
hydrogen was bubbled through the solution three consecutive times to promote efficient 
reduction. Completion of the reaction was monitored using TLC analysis (Hex:EA = 1:1). A 
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final ninhydrin stain (C:M = 9:1) confirmed reduction of the carboxybenzyl group to a free 
amine. The palladium was removed by filtration through a pad of celite and the product was 
concentrated to dryness.  
Compound 20 - Synthesis of Nε-NBoc-L-thiazolidine-Methylester 	
 N-boc-L- thiazolidine-4-carboxylicacid (1.0 eq.) was dissolved in dichloromethane 
(40ml). Next, DMAP (0.5 eq.) was added followed by subsequent addition of EDC (1.2 eq.). 
After an hour of stirring at 0o C, Boc-L-Lysine Methylester (previously dissolved in 5 mL DCM) 
was added dropwise. Completion of the reaction was monitored using TLC analysis (Hex:EA = 
1:1, iodine stain). The mixture was diluted with dichloromethane (50 ml) and extracted with 1M 
HCl (50 ml) and brine (50 ml). The organic fractions were dried with magnesium sulfate and 
concentrated to dryness to give the crude product. The product was purified using column 
chromatography hexane: ethyl acetate = 3:1 in which mass spec and NMR analysis helped in 
identifying of the compound.  
Compound 21 - Synthesis of Nε-(N-boc-thiazolidine)  
Nε-(N-boc-L-thiazolidine)]-O-methylester (1 eq.) was dissolved in THF:H2O (3:1, 36 mL), 
followed by addition of LiOH·H2O (2 eq.). The reaction was stirred at room temperature 
overnight and the reaction was monitored using TLC analysis (hexane: ethyl acetate = 1:1, iodine 
stain). The reaction mixture was diluted with ethyl acetate (30 ml) and water (30 ml) and the 
aqueous layer with acidified using a 5% citric acid solution, (pH ~ 4.0). The aqueous layer was 
then extracted twice with ethyl acetate (30 ml) and then with brine (30 ml). The combined layers 
were dried, filtered, and concentrated to dryness.  
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Compound 22 - Synthesis of Nε-L-Thiaprolyl-L-lysine  
 [Nε-(N-boc-thiazolidine)] (1 eq.) was dissolved in dichloromethane (10 mL) and cooled 
to 0O C. Afterwards, trifluoroacetic acid (5 mL) was added dropwise and the reaction was stirred 
overnight. The oil product was dissolved in H2O (20 mL) and extracted twice with diethyl ether 
(20 mL). The recovered aqueous layer was concentrated to dryness under reduced pressure, to 
yield L-lysine(Nε-thiazolidine) (Nε-L-Thiaprolyl-L-lysine). NMR and mass spec analysis 
confirmed synthesis of the product. 
Compound 23 - Synthesis of Nε-L-Thiaprolyl-L-lysineOMe  
 [Nε-(N-boc-thiazolidine)] (1 eq.) was dissolved in 1,2-dioxane and stirred at room 
temperature. 4M hydrogen chloride in dioxane was added dropwise and the reaction was allowed 
to stir overnight, which resulted in formation of a white precipitate. Excess solvent was removed 
through evaporation and the crude was further purified using ether precipitation (3700 rpm, 10 
min, 4o C). The product was allowed to dry and NMR analysis granted successful synthesis of 
the product.  
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3 INCORPORATION OF THZK INTO UBIQUITIN 
3.1 Expression of UbK11ThzK via Incorporation of UAA 
Both synthesized unnatural amino acids (methylated and non-methylated forms) were 
incorporated site-specifically into ubiquitin at the K11 position. Formation of the peptides were 
confirmed by MALDI.  
3.1.1 Selection Markers 
 Selectable markers are utilized to identify cells containing a specific trait. 
Introducing a selectable marker allows certain colonies to uptake a plasmid containing the gene 
of choice. Most of these markers promote resistance to specific antibiotics and colonies that 
successfully take up the plasmid will most likely develop resistance against a particular 
antibiotic. In the expression of UbK11ThzK, plasmids encoding the vectors pMyo-Ubk11TAG-
Tet and pBk-ThzPylr-Amp contained tetracycline and ampicillin resistant genes, respectively.21  
 
Figure 3.1 Structures of Ampicillin and Tetracycline 
 
 
 The antibiotics are used as selectable markers for gene resistance in protein expressions. 
Introduction of the antibiotic gene into the vector is achieved by recombination techniques, 
which is then transformed into cells. Replicating cells containing recombinant DNA molecules 
develop resistance against these antibiotics. 
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3.1.2 Translation 
 Incorporation of UAAs can be utilized to create proteins with unique functions.  
We have shown successful selective incorporation for both methylated and non-methylated 
unnatural amino acids into ubiquitin at the K11 position, although the yield reported for the 
methylated form shows higher selectivity. Site-specifically introducing an UAA requires 
construction of an orthogonal aaRS-tRNA pair that uses an amber suppressor codon to 
incorporate an UAA into the protein of interest. The amber codon triplet in DNA is TAG and in 
mRNA UAG. Instead of terminating protein translation, use of amber codon suppression 
incorporates the UAA as a coding codon in translation. Therefore, evolution of an aaRS-tRNA 
pair is necessary so that it no longer recognizes natural amino acids, only the UAA of interest. 
Here, our engineered aaRS, Pyrrolysyl tRNA synthetase, is developed through cloning 
techniques and encoded in the vector pBk-ThzPylr-Amp. The cognate tRNA can be 
aminoacylated by the aaRS and charged with our synthesized UAA to be incorporated into 
ubiquitin at the K11 position through amber suppression. The amber codon triplet is encoded in 
the vector pMyo-Ubk11TAG-Tet.22 
Incorporation of the UAA involves aminoacylation of tRNAPyl with the cognate PylRS. 
The tRNA is charged with the amino acid, which is incorporated into the protein sequence site-
specifically through recognition of an amber stop codon.21,22  
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Figure 3.2 Nonsense Amber Suppression 
 
 
Occurs when a stop codon, such as UAG, is decoded as an amino acid instead of 
terminating protein synthesis. This allows incorporation of an UAA into the peptide sequence for 
a given protein. The tRNA bearing the anticodon sequence is aminoacylated by its cognate aaRS 
and charged with the appropriate amino acid. The mRNA codon is matched with the anticodon 
of the tRNA carrying the UAA, which facilitates the incorporation of a UAA at a specific site in 
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a peptide sequence. Incorporation of the UAA site-specifically yields the protein of interest, 
which can be isolated through purification techniques.21 
 
3.1.3 Incorporation of Methylated ThzK 
Our results show successful incorporation of the methylated UAA into ubiquitin at the 
K11 position. Here, we focus on utilizing cultures inoculated with DH10B E. coli stock solutions 
containing the recombinant plasmids as indicated.  
The following expression is presented to show how the yield for each expression is 
calculated. Following multiple successive lysis and wash buffers during purification of the 
expressed protein and is eluted using 5 mL intervals. The absorbance for each elution is 
measured at OD595. Appropriate calculations are determined at an absorbance above 0.100, as an 
absorbance under this value reciprocate insignificant yield values. The total yield is calculated 
based on each elution measured. Incorporation of the synthesized UAA is shown in Figure  
 
Elution (5 ml) UbK11ThzKOMe-4 
1 OD595 = 0.596 = mg 
2 OD595 = 0.361 = mg 
3 OD595 = 0.138 = mg 
4 OD595 = 0.122 = mg 
5 OD595 = 0.104 = mg 
6 OD595 = 0.096 insignificant 
  Total = 66 mg 
 
Figure 3.3 Yield for Incorporation of Methylated UAA 
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Figure 3.4 Calculation from the Standard Curve for Yield Calculation 
 
 
 
The concentration of the sample is monitored at OD595 and utilized in the equation above. 
Note that the equation produces values in mg/ml and the overall yield is determined depending 
on the total volume of elution buffer utilized.  
 
 
Our yield calculations are defined from a standard graph plotting absorbance versus 
concentration, where the linear equation of increasing absorbance in relation to concentration is 
generated. The equation can be arranged to allow calculation of the yield utilizing the absorbance 
of the elution. According to Beer’s law, absorbance of a sample is proportional to the 
concentration. Therefore, the absorbance is reflective of the concentration at any point in the 
curve, where decreasing concentrations correspond to a lower absorbance and increasing 
concentrations have a higher absorbance. The optical density of any region should be 
proportional to the surface protein concentration as the concentration approaches 1. Therefore, 
appropriate yields are calculated at a concentration at or above 0.100, but no larger than 1. 
OD595 + 0.0245
0.03945
2.4 ul  = mg/ml .. 3
4.8 ul  = mg/ml .. 6
8.0 ul  = mg/ml .. 10
= X mg/ml
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Figure 3.5 Linear Equation Developed from Molar Concentration in Relation to Absorbance 
 
 
The linear equation can be arranged and applied to calculate the yield for an entire 
protein expression using the absorbance of the sample at a given OD. The linear equation was 
obtained from measuring the absorbance for a series of protein expressions and calculating the 
concentration utilizing Beer’s law.  
 
Incorporation of the methylated UAA showed higher yields compared to the non-
methylated form, which indicates improved target affinity and membrane permeability for the 
methylated UAA. Yields for the methylated UAA were favorable. Proteins bound to the Ni2+ 
resin were purified with lysis and two successive portions of wash buffers. The proteins were 
then eluted with six 5mL portions of elution buffer, notated as E1 through E6. The first elution 
band (E1) shows the overexpressed protein of interest at 11kDa. Impurities are few, compared to 
the incorporation of non-methylated UAA. The results are obtained from a 2L culture. 
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A
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1
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Figure 3.6 Expressed Protein from Incorporation of Methylated UAA 
 
Proteins tagged with an HA hemagglutinin tag can be easily identified in Western blot 
techniques. This antibody is used to detect HA tag of target protein expressed in DH10B cells. 
Cell lysates were loaded onto a 4-20% Tris-HCl polyacrylamide gel. Proteins were separated 
using SDS-PAGE, transferred to a PVDF membrane, and blocked with 5% nonfat milk diluted in 
0.1% TBS. The membrane was probed with the HA tag at a dilution of 1:500 overnight at 4o C, 
and then probed with a secondary antibody at a dilution of 1:10,000 for an hour at room 
temperature. The membrane was washed with a 0.1% TBS buffer before and after addition of the 
secondary antibody. Lysates containing a multi-epitope tagged protein are visualized in Figure 
3.7, although the band of interest is strongly exhibited at 11kDa.   
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Figure 3.7 Western Blot Analysis on Incorporated UAA 
 
 
3.1.4 Incorporation of Non-Methylated ThzK 
Non-methylated UAAs were incorporated into ubiquitin at the K11 position, as indicated 
by coomassie staining. Proteins bound to a Ni2+ resin were purified with lysis and two successive 
portions of wash buffers. The proteins were then eluted with 1mL portions of elution buffer, 
notated as E1 through E3. Results indicate three attempts for incorporation of the UAA for a 500 
ml culture. The yield for each trial averages to about 7 mg from a 500 ml culture. Elution bands 
show small amount of expressed protein at 11kD, and multiple impurities, suggesting low 
incorporation and selection for the synthesized UAA.  
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Figure 3.8 Incorporation of Non-Methylated UAA 
 
Three separate trials for incorporation of non-methylated UAA were performed. 
Coomassie staining indicates low affinity and permeability for non-methylated UAA. The 
calculated yield for each expression averages around 6mg for a 500 mL culture. Multiple 
impurity bands are also visualized in the elution lanes, suggesting decreased incorporation of the 
UAA. Incorporation of methylated UAA is believed to show better incorporation in cells as it is 
less charged compared to the non-methylated UAA, which could possibly facilitate better 
delivery into cells. Cells also contain an esterase enzyme to easily cleave the methoxy group.  
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3.2 Deprotection of UbK11ThzK 
The incorporated UAA undergoes de-protection to generate a nucleophilic N-terminal 
cysteine residue utilizing a O-methylhydroxyamine in a 6M solution of guanidium chloride. 
Generation of the cysteine residue permits ligation of the acceptor Ub to a donor Ub via native 
chemical ligation, creating our di-Ub probe 3, essential for conjugation to an E2 enzyme. 
Deprotection of ThzK to CysK is confirmed by MALDI analysis.  
 
 
Figure 3.9 Deprotection of ThzK to CysK 
 
 
Generation of a cysteine residue that is capable of nucleophilic attack on a donor 
ubiquitin molecule. The acceptor molecule becomes ligated to the donor ubiquitin, facilitating 
production of a di-Ub conjugate. 
 
3.3  Conclusions 
 Incorporation of the methylated UAA into ubiquitin at the K11 position is more sufficient 
compared to the non-methylated UAA, as exhibited in coomassie and MALDI analysis. Higher 
yields and fewer impurities are obtained. 
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3.4 Methods and Materials 
Expression of UbK11ThzK 
A starting culture was prepared with 5 ml of 2XYT media containing tetracyclin and 
ampicillin (1:1000 dilution). The media was inoculated with DH10B E. coli cells to yield 
tetracyclin and ampicillin resistant cells, encoding vectors pMyo-UbK11TAG-Tet and pBk-
ThzPyls-Amp. After overnight growth (37o C, 280 rpm), 1 ml of the starting culture was 
inoculated into four 500 mL (2L) flasks containing sterile media. To this, the antibiotics (1:1000 
fold) were added and the cultures were incubated (37o C, 280 rpm) until OD600 = 0.6 – 0.8. The 
previously synthesized amino acid Nε-L-Thiaprolyl-L-lysine (2 mM, 1.42g) was dissolved in 
H2O and NaOH (3 ml, 1 ml, pH 8.0) and added to the cultures. After 30 minutes, the cells were 
induced with Isopropyl D-1-thiogalactopyranoside and 20% arabinose (1:1000 dilution) and 
incubated overnight (30o C, 280 rpm). The cells were harvested by centrifugation at rcf 8000 x 
gravity (4 o C, 30 min) and then re-suspended in lysis buffer.  Lysosome (10 ml/L), magnesium 
chloride (10 uL/L), calcium chloride (10 uL/L), phenylmethylsulfonyl fluoride (200 uL/L) and 
dithiothreitol (20 uL/L) were added to promote cell lysis. The cells were sonicated (19%, 30 
min., 10s impulses) and centrifuged (12000 rpm, 30 min, 4 o C), in which the supernatant was 
collected and incubated overnight in a prepared Ni 2+ resin (4 o C). The protein was purified with 
portions of lysis, wash, and elution buffers, respectively and confirmed by MALDI analysis. The 
protein was dialyzed (1L, 50 mM TRIS, 50 mM NaCl, 1 mM DTT, pH 8.0). After dialysis, the 
protein was lyophilized, deprotected (5h, 37o, C), dialyzed again, and purified via HPLC.  
Deprotection of ThzK  
UbK11ThzK was dissolved in 1 mL 6M solution of guanidium chloride in 100 mM 
phosphate buffer, pH 8.0. O-methylhydroxyamine hydrochloride was added to the solution at a 
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final concentration of 200 mM. The pH was adjusted to 4.0 and the solution was incubated at RT 
for 4h. The protein was dialyzed into PBS buffer containing 1 mM DTT and then into 20 mM 
ammonium bicarbonate containing 1 mM DTT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
4 SYNTHESIS OF UBK11CYSUB 
 This chapter will focus on synthesis of the di-Ub probe, which involves expression of the 
donor Ub, UBSR, and conjugation to the acceptor Ub, CysK. The two ubiquitin molecules are 
ligated and undergo S-N acyl transfer. Ligation of the two deprotected peptides was confirmed 
with MALDI/MS. 
 
4.1 Linkage Specific Di-Ub Synthesis through Native Chemical Ligation 
Synthesis of 3 involves expression of a donor Ub bound to intein tag for affinity 
purification of the fusion protein on chitin resin. Addition of a thiol compound results in 
cleavage of the donor Ub from the intein tag, which is purified via affinity chromatography. The 
donor Ub can then be ligated to our acceptor Ub via native chemical ligation to yield 15, which 
undergoes S to N acyl transfer giving the resulting product 3. 
 
Figure 4.1 Intein Mediated Thiol Cleavage 
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4.2 Expression of UBSR 
Early engineered inteins have allowed the development of self-cleaving affinity tags and 
methods for combining protein segments through protein ligation. UBSR expression involves a 
modified intein that is expressed in fusion to an affinity tag. Cleavage of the intein and tag from 
the target protein occurs during induction of the intein and after the fusion if affinity-purified. 
The cleavage activity of inteins are triggered by the addition of thiol compounds. The addition of 
MESNA via thiol mediated cleavage separates our target protein, UBSR, from the intein-tag 
complex and generates a good sulfonate leaving group upon addition of an acceptor peptide 
during chemical ligation.8  
 During the purification of UBSR via affinity column, the intein and affinity tag 
binds to a chitin resin. The resin is washed with a wash buffer containing 1 mM EDTA and 
TCEP to elute undesirable proteins. Elution buffer containing 200mM MESNA is added to the 
resin and capped overnight at room temperature to allow sufficient thiol mediated cleavage of the 
target protein. The protein is eluted, leaving behind the intein and afftinity tag. The donor Ub can 
then undergo chemical ligation with an acceptor Ub to generate a di-Ub conjugate.  
The donor Ub can be ligated to an acceptor Ub only after successful cleavage from the 
intein. Before cleavage, the protein-intein complex undergoes N-S acyl transfer to generate a 
thioester product. Addition of MESNA separates the target protein from the intein, facilitating a 
thiol mediated cleavage. An acceptor Ub molecule can be ligated to the donor Ub by 
nucleophilic attack on the C-terminal of the donor Ub. The two ligated peptides undergo another 
S-N acyl transfer to produce the target di-Ub probe. 
The target protein was purified via column purification after cleavage with MESNA. The 
results are visualized in Figure 4.2. In the fourth and fifth wash lanes, a band near 30 kDa is 
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shown, representative of fused intein bound UBSR protein obviously not bound to the chitin 
resin. UBSR, 8.5 kDa, is visualized in the last elution lane. There are small traces of protein at a 
higher molecular weight, corresponding to fused intein-UBSR and intein only at kDa, 
respectively. The sixth lane shows a sample taken directly from the chitin resin with the same 
bands indicated in the elution band. However, the intein band is much more intense compared to 
the elution band.  
 
 
Figure 4.2 Expression of Donor Ubiquitin 
 
Coomassie analysis for expressed donor molecule, visualized at 8.5 kDa. Protein is 
treated with MESNA (1 mM, overnight, RT) and subjected to purification via Ni2+ resin.  
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4.3 Native Chemical Ligation of UbK11CysUb 
Here, we prepare 3, which we can further conjugate with a specific E2 enzyme to 
construct our target di-Ub-E2 probe. Formation of our di-Ub probe is discussed.  
 
Figure 4.3 Formation of DiUb Probe through Native Chemical Ligation 
 
Both expressed donor and acceptor Ub molecules were successfully ligated using native 
chemical ligation. Formation of the di-Ub product is monitored at 0, 2, and 4 hours and 
overnight. The donor molecule is used in excess (1.5 eq.) to promote formation of the di-Ub 
product, which is visualized by overexpression at 8.5kDa during all time intervals. The acceptor 
9 (11 kDa) is diminished over the time period a, while formation of 3 (19 kDa) increases. 
acceptor and di-Ub product itself are similar in structure and each carry a bound His tag. The 
donor Ub is easily purified using affinity purification considering the lack of a bound His tag. 
Purification of 12 is shown in the flowthrough and lysis lanes in Figure. It is rather challenging 
to separate compounds 9 and 3 via affinity purification alone considering bound His tag. The 
elution lanes contain overexpression of 3, although some unconverted acceptor Ub is visiualized.  
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Figure 4.4 Expression of UbK11CysUb 
 
The donor Ub molecule (8.5 kDa) is added in excess to ensure most of reactant 9 is 
converted into product 3. Formation of the di-Ub conjugate is monitored over a period of 0, 2, 
and 4 hours as well as an overnight reaction. Depletion of reactant 9 is visualized over the time 
intervals as formation of 3 increases. The acceptor and di-Ub conjugate both contain a His tag, 
while the donor lacks this tag. Therefore, unutilized donor 12 can be purified via column 
chromatography rather easily. Overexpression of 3 is visualized in the two elution bands, 
although a small trace amount of 9 is present to difficulty in separation of the two compounds via 
affinity purification.  
4.4 Conclusions 
The Di-Ub conjugate 3 was successfully synthesized after expression and purification of 
the donor Ub molecule 12, following native chemical ligation to the acceptor Ub 9.  
La   0   2    4   o/n  dia La  F   L   W1   W2   E1    E2
UBSR
CysK
di-Ub
kDa
245
190
135
100
80
58
46
32
25
22
17
11
50 
4.5 Methods and Materials 
Expression of UBSR 
A 5 ml starting culture was prepared with 2XYT broth and inoculated with ampicillin 
(1:1000 fold) and BL21 cells containing the vector pBk-ThzPyls-Amp. 1 ml of the starting 
culture was inoculated into four 1L flasks (4L total), which was incubated (37o C, 280 rpm) until 
OD600 = 0.8. The cells were induced with IPTG (1:1000) and after 30 minutes transferred to the 
refrigerated shaker overnight. Harvesting of the cells required centrifugation at rcf 8000 x gravity 
(4 o C, 30 min) and resuspension in column buffer (20 mM Na2HPO4, 200 mM NaCl, 1 mM 
EDTA, 1 mM TCEP, 20 uM PMSF) for an hour. After resuspension, the cells were sonicated for 
30 minutes (19%, 10s impulses) and spun down via centrifugation (12000 rpm, 30 min, 4 o C). 
The protein was purified using Intc resin with two successive portions of wash buffer: wash I 
(1mM EDTA, 1 mM TCEP, pH 7.2) wash II (1mM EDTA, 10 mM TCEP, pH 7.2), respectively. 
Elution buffer (1mM EDTA, 10 mM TCEP, 200 mM MesNa) was added to the column and 
capped for overnight incubation at room temperature, which was eluted the following day.  
Ligation – UbK11CysUb 
CysK (11.5kDa, 340 nmol, 3.92 mg) was dissolved in 200 ul of ligation buffer (recipe) 
and the absorbance was monitored at OD595. Purified UBSR (8.5kDa, 1367 nmol,11.62 mg) 
measured at OD595 was allowed to react (in 1.5 equivalence) with the acceptor ubiquitin 
overnight under inert conditions. Fractions taken at 0, 2, 4, and overnight intervals (5 ul 
dissolved in 80 ul H2O) were collected to be analyzed for coomassie and western blot analysis. 
The protein was dialyzed (100 ml 10x phosphate, 900 ml H2O, 1mM DTT, pH 8.0) and allowed 
to incubate on Ni2+ overnight at 4o C. The protein was purified with portions of lysis, wash 
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(5ml), and elution buffer (1.5ml) and the elution fractions containing an absorbance > 0.1 at 
OD595 were dialyzed even further.  
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5 PREPARATION OF DIUB-E2 CONJUGATE 
This section covers the expression of an E2 enzyme, Ube2s, which is further conjugated 
with our di-Ub probe to better understand how ubiquitin chains are formed through E2 catalyzed 
reactions.  
 
5.1 Expression of Ube2s 
The E2 enzyme Ube2s is bound to a SUMO-His tag which is cleaved with addition of 
Ulp1 to generate the target E2 protein. Catalytic activity of Ulp1 involves hydrolysis of the 
alpha-linked peptide bond in the sequence Gly-Gly-Ala-Thr-Tyr at the C-terminal end of small 
ubiquitin like modifier protein (SUMO) and cleaves between the second Gly and Ala residues. 
The protease is highly specific for SUMO protein fusion and recognizes the tertiary structure of 
SUMO rather than amino acid sequence.17,27  
 
Figure 5.1 Cleavage of Ube2s by Addition of Ulp1 
Ulp1
His
Gly-Gly-Ala-Thr-Tyr
His
SUM O Ube2s
SUMO Ube2s
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The expressed protein was purified via affinity column using Ni2+ resin. Eluted samples 
containing Ube2s with bound SUMO peptide (E1 to E6) were subjected to dialysis (1x TBS, 1 
mM DTT) twice and treated with Ulp1 (2 mL). Purification of the target protein (17 kDa) was 
achieved through additional affinity chromatography leaving the SUMO-His bound to Ni2+ resin. 
The expressed cleaved protein is visualized in elutions 7 through 10 (E1 – E10), although high 
yield of the protein was obtained in elution 9.  
 
 
Figure 5.2 Expression of Ube2s 
 
Coomassie Stain showing expressed protein before and after addition of Ulp1. Before 
addition of the protease, the protein is purified via affinity purification using Ni2+ resin and 
eluted as shown from E1 to E6. The eluted proteins are treated with a 2 mL solution of Ulp1 and 
purified further via Ni2+ resin in which the SUMO tag has high affinity for the column. The 
target protein is visualized at kDa 17. 
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The addition of di-Ub probes to covalently trap enzymes could address structural and 
biochemical studies of Ub linkage specificity. Current work is centered on conjugating our 
expressed E2 protein 24 with the synthesized di-Ub probe 3 through disulfide bond formation in 
hopes of retrieving a clear crystal structure through X-ray crystallography of the intact di-Ub-E2 
conjugate. The ability of E2-Ub conjugates to transfer Ub can be explored by assessing their 
reactivity towards nucleophiles such as free lysine. Ubiquitin associates with a cysteine in the 
active site of an E2 through its C-terminal end. During Ub chain synthesis catalytic activity of 
the E2 enzyme requires proper conformation and orientation to allow nucleophilic attack and 
subsequent linkage of the acceptor Ub to an existing chain. In situ, the point at which an acceptor 
Ub molecule becomes covalently linked to a donor Ub within the active site of the E2 is transient 
and rather difficult to map. Therefore, construction and conjugation of a stable di-ub probe to an 
E2 enzyme provides leeway for addressing areas of ubiquitin elongation involving multiple 
protein interactions. The di-Ub-E2 probe can be exposed to a multitude of substrates, 
deubiquitinating enzymes (DUBs), and other cascade proteins to better understand mechanisms 
of ubiquitin transfer.  
Construction of the di-Ub-E2 conjugate 25 through disulfide bridge linkage is derived by 
coupling through oxidation of two thiol groups. Formation of a disulfide bond provides stability 
of a protein in its respective conformation and plays an important role in folding and stability. 
Another approach for synthesis of of the di-Ub-E2 conjugate is through elimination of cysteine 
to dehydroalanine (Dha), which is a useful precursor to a range of post translational 
modifications of proteins by conjugation of a thiol. Our E2 can then be conjugated with the 
reduced product via Michael addition reaction.28  
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Figure 5.3 Bis-Alkylation of Cysteine to Dha 
 
The cysteine of the di-Ub probe 3 undergoes an elimination reaction, similar to Figure 
5.3, with a, a’– dibromoadipic-bis-amide (DBAA), which activates the cysteine residue for 
elimination under basic conditions. The product can then be coupled with an E2 enzyme forming 
product 26 in Figure 5.4.1 
 
 
Figure 5.4 Formation of DiUb-E2 Conjugate via Disulfide and Michael Addition Reactions 
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5.2 Conclusions 
Our Di-Ub-E2 probe is derived from conjugating a specific E2 enzyme with our 
synthesized Di-Ub. Construction of the Di-Ub involves chemically modifying a natural amino 
acid and site specifically incorporating it into the K11 position of ubiquitin with the use of an 
orthogonal tRNA/tRNA synthetase pair. Once incorporated, our acceptor Ub is de-protected to 
generate a reactive cysteine species which undergoes native chemical ligation with an expressed 
donor Ub, facilitating production of the Di-Ub molecule.  
The stable di-Ub-E2 conjugate can be utilized to mimic the transition state during linkage 
of an acceptor Ub molecule to a donor Ub catalyzed by an E2 enzyme. Here we hope to uncover 
a three-dimensional structure of the conjugate to expand understanding on the mechanisms 
behind ubiquitin chain synthesis. Current work involves expressing proteins for the conjugated 
diUb-E2 probe.  
 
5.3 Methods and Materials 
Expression of Ube2s 
A 20 ml starting culture was prepared with 2XYT broth and inoculated with kanamycin 
(1:1000 fold) into a BL21 cell line. The starting culture was equally inoculated into four 1L 
flasks (4L), which was incubated (37o C, 280 rpm) until OD600 = 0.8. The cells were induced 
with IPTG (1:1000) and after 30 minutes transferred to the refrigerated shaker (18o C) overnight. 
Harvesting of the cells required centrifugation at rcf 8000 x gravity (4o C, 30 min) and 
resuspension in lysis buffer for an hour. After resuspension, the cells were sonicated for 30 
minutes (19%, 10s impulses) and spun down via centrifugation (12000 rpm, 30 min, 4 o C). The 
protein was purified using Ni2+ resin with lysis and two successive portions of wash buffer, 
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respectively. The eluted proteins were dialyzed (50 mM TRIS, 50 mM NaCl, 1 mM DTT, pH = 
8.0) twice and treated with a solution (2 mL/mg) of Ulp1. Proteins were further purified using 
affinity purification with Ni2+ resin to facilitate removal of SUMO tag.  
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APPENDICES  
1H-NMR Analysis of Compound 23 ThzKOMe 
 
1H NMR (400 MHz, D2O) δ 4.55 (t, J = 6.8 Hz, 1H), δ 4.41 (d, J = 10 Hz, 1H), δ 4.33 (d, J = 10 
Hz, 1H), δ 4.05 (t, J = 6.0, 1H), δ 3.74 (s, 3H), δ 3.48- 3.43 (m, 1H), δ 3.24 – 3.11 (m, 3H), δ 
1.96 – 1.79 (m, 2H), δ 1.52 – 1.40 (m, 2H), δ 1.39 – 1.27 (m, 2H) 
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1H-NMR Analysis of Compound 22 ThzKOH 
 
1H NMR (400 MHz, D2O) δ 4.55 (t, J = 6.8 Hz, 1H), δ 4.38 (d, J = 10 Hz, 1H), δ 4.32 (d, J = 10 
Hz, 1H), δ 3.88 (t, J = 6.0, 1H), δ 3.46- 3.40 (m, 1H), δ 3.24 – 3.11 (m, 3H), δ 1.90 – 1.76 (m, 
2H), δ 1.54 – 1.45 (m, 2H), δ 1.40 – 1.25 (m, 2H) 
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Electrospray Ionization for ThzKOMe 
 
 
 
 
 
 
 
 
 
 
 
 
HZ_5_21_THZK_OME_T5_ESIPOS_YIN_071817 #142-149 RT: 2.01-2.11 AV: 8 NL: 2.80E7
T: FTMS + p ESI Full ms [50.00-1000.00]
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MALDI Characterization for Incorporated UAA – UbK11ThzK 
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MALDI Characterization of Deprotected CysK 
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MALDI Characterization of UbK11CysUb 
 
 
 
 
